. "Nikiforow S, Mahadeo K, Chaganti S, et al. Subgroup analysis based on prior treatment from the phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease [abstract].
                    <i>Blood.</i>
                    2025;146(suppl 1):1934.." Blood, 2026. doi:10.1182/blood.2026033858